Effective at the market close on Thursday, November 4, KDMN will be removed from the LifeSci Biotechnology Clinical Trials Index and its value will be redistributed to the remaining index components based on their weights.
On September 8, 2021, Kadmon Holdings, Inc. agreed to be acquired by AstraZeneca plc for $9.50 per share in cash.
